KIR2DS2+ NK cells in cancer patients demonstrate high activation in response to tumour-targeting antibodies.
Graham LV, Fisher JG, Doyle ADP, Sale B, Del Rio L, French AJE, Mayor NP, Turner TR, Marsh SGE, Cragg MS, Forconi F, Khakoo SI, Blunt MD.
Graham LV, et al. Among authors: turner tr.
Front Oncol. 2024 Sep 2;14:1404051. doi: 10.3389/fonc.2024.1404051. eCollection 2024.
Front Oncol. 2024.
PMID: 39286025
Free PMC article.